Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus

Table 4 Adverse events related to sorafenib administration and transarterial chemoembolization in the two groups n (%)

Adverse event	Group A	Group A	P
	(n = 37)	(n = 31)
Sorafenib related AEs
Hand-foot skin reaction
Grade 1-2	26 (92.9)	27 (96.4)	0.143
Grade 3-4	2 (7.1)	1 (3.6)	0.593
Diarrhea
Grade 1-2	23 (88.5)	18 (94.7)	0.994
Grade 3-4	3 (11.5)	1 (3.6)	0.620
Hypertension
Grade 1-2	8 (21.6)	6 (19.4)	0.818
Grade 3-4	1 (3.2)	0	1.000
Alopecia
Grade 1-2	2 (7.1)	4 (12.9)	0.400
Grade 3-4	0	0
Fatigue
Grade 1-2	9 (24.3)	4 (12.9)	0.354
Grade 3-4	0	0
Voice change
Grade 1-2	0	1 (3.6)	464
Grade 3-4	0	0
Epistaxis
Grade 1-2	2 (7.1)	2 (6.5)	1.000
Grade 3-4	0	0
TACE related AEs
New ascites	4 (10.8)	11 (35.5)	0.020
Liver dysfunction	2 (16.2)	15 (48.4)	< 0.000
Gastrointestinal hemorrhage	0	8 (25.8)	0.001
Hepatorenal syndrome	0	2 (6.5)	0.204
Liver abscess	0	0	-
Spontaneous bacterial peritonitis	0	0	-
Inguinal hematoma	0	0	-
Pulmonary/cerebral oil embolization	0	0	-

TACE: Transarterial chemoembolization.